ID

31631

Description

Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00924807

Link

https://clinicaltrials.gov/show/NCT00924807

Keywords

Versions (1)
  1. 9/14/18 9/14/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

September 14, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Prostate Cancer NCT00924807

English

Eligibility Prostate Cancer NCT00924807

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients must have histologically confirmed intermediate or high risk prostate adenocarcinoma. intermediate risk disease comprises t2b/c tumors, gleason 7 histology, or psa 10-20. high risk tumors comprise t3-4, gleason 8 or higher histology, or psa greater than 20.
Description

Adenocarcinoma of prostate Intermediate Risk | Adenocarcinoma of prostate High risk | TNM clinical staging | Gleason score | Prostate specific antigen measurement

Data type

boolean

Alias
UMLS CUI [1,1]
C0007112
UMLS CUI [1,2]
C3640764
UMLS CUI [2,1]
C0007112
UMLS CUI [2,2]
C4319571
UMLS CUI [3]
C3258246
UMLS CUI [4]
C3203027
UMLS CUI [5]
C0201544
age > 18 years.
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
life expectancy of greater than 5 years.
Description

Life Expectancy

Data type

boolean

Alias
UMLS CUI [1]
C0023671
patients must have normal organ and marrow function.
Description

Organ function | Bone Marrow function

Data type

boolean

Alias
UMLS CUI [1]
C0678852
UMLS CUI [2,1]
C0005953
UMLS CUI [2,2]
C0031843
no pelvic lymph node metastases based on pelvic ct scan or mri.
Description

Absence Secondary malignant neoplasm of lymph node Pelvic CT of Pelvis | Absence Secondary malignant neoplasm of lymph node Pelvic MRI of Pelvis

Data type

boolean

Alias
UMLS CUI [1,1]
C0332197
UMLS CUI [1,2]
C0686619
UMLS CUI [1,3]
C0030797
UMLS CUI [1,4]
C0412628
UMLS CUI [2,1]
C0332197
UMLS CUI [2,2]
C0686619
UMLS CUI [2,3]
C0030797
UMLS CUI [2,4]
C0203201
no bone metastasis. a whole body bone scan is required to rule out metastatic disease.
Description

Secondary malignant neoplasm of bone Absent | Whole body bone scan Required

Data type

boolean

Alias
UMLS CUI [1,1]
C0153690
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C3863086
UMLS CUI [2,2]
C1514873
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
any previous, radiotherapy, or chemotherapy, or more than 4 weeks of androgen deprivation hormonal therapy for the treatment of prostate adenocarcinoma.
Description

Prior radiation therapy Adenocarcinoma of prostate | Prior Chemotherapy Adenocarcinoma of prostate | Antiandrogen therapy Adenocarcinoma of prostate

Data type

boolean

Alias
UMLS CUI [1,1]
C0279134
UMLS CUI [1,2]
C0007112
UMLS CUI [2,1]
C1514457
UMLS CUI [2,2]
C0007112
UMLS CUI [3,1]
C0279492
UMLS CUI [3,2]
C0007112
patients may not be receiving any other investigational agents.
Description

Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C0013230
history of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib or other agents used in this study.
Description

Allergic Reaction Compound Sorafenib Similar | Allergic Reaction Compound Investigational New Drugs Similar

Data type

boolean

Alias
UMLS CUI [1,1]
C1527304
UMLS CUI [1,2]
C1706082
UMLS CUI [1,3]
C1516119
UMLS CUI [1,4]
C2348205
UMLS CUI [2,1]
C1527304
UMLS CUI [2,2]
C1706082
UMLS CUI [2,3]
C0013230
UMLS CUI [2,4]
C2348205
known human immunodeficiency virus (hiv) infection or chronic hepatitis b or c.
Description

HIV Infection | Hepatitis B, Chronic | Hepatitis C, Chronic

Data type

boolean

Alias
UMLS CUI [1]
C0019693
UMLS CUI [2]
C0524909
UMLS CUI [3]
C0524910
patients receiving anti-coagulation treatment with an agent such as warfarin or heparin will not be allowed to participate.
Description

Anticoagulation Therapy | Warfarin | Heparin

Data type

boolean

Alias
UMLS CUI [1]
C0003281
UMLS CUI [2]
C0043031
UMLS CUI [3]
C0019134
Back to the top of the page

Similar models

Eligibility Prostate Cancer NCT00924807

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Adenocarcinoma of prostate Intermediate Risk | Adenocarcinoma of prostate High risk | TNM clinical staging | Gleason score | Prostate specific antigen measurement
Item
patients must have histologically confirmed intermediate or high risk prostate adenocarcinoma. intermediate risk disease comprises t2b/c tumors, gleason 7 histology, or psa 10-20. high risk tumors comprise t3-4, gleason 8 or higher histology, or psa greater than 20.
boolean
C0007112 (UMLS CUI [1,1])
C3640764 (UMLS CUI [1,2])
C0007112 (UMLS CUI [2,1])
C4319571 (UMLS CUI [2,2])
C3258246 (UMLS CUI [3])
C3203027 (UMLS CUI [4])
C0201544 (UMLS CUI [5])
Age
Item
age > 18 years.
boolean
C0001779 (UMLS CUI [1])
Life Expectancy
Item
life expectancy of greater than 5 years.
boolean
C0023671 (UMLS CUI [1])
Organ function | Bone Marrow function
Item
patients must have normal organ and marrow function.
boolean
C0678852 (UMLS CUI [1])
C0005953 (UMLS CUI [2,1])
C0031843 (UMLS CUI [2,2])
Absence Secondary malignant neoplasm of lymph node Pelvic CT of Pelvis | Absence Secondary malignant neoplasm of lymph node Pelvic MRI of Pelvis
Item
no pelvic lymph node metastases based on pelvic ct scan or mri.
boolean
C0332197 (UMLS CUI [1,1])
C0686619 (UMLS CUI [1,2])
C0030797 (UMLS CUI [1,3])
C0412628 (UMLS CUI [1,4])
C0332197 (UMLS CUI [2,1])
C0686619 (UMLS CUI [2,2])
C0030797 (UMLS CUI [2,3])
C0203201 (UMLS CUI [2,4])
Secondary malignant neoplasm of bone Absent | Whole body bone scan Required
Item
no bone metastasis. a whole body bone scan is required to rule out metastatic disease.
boolean
C0153690 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C3863086 (UMLS CUI [2,1])
C1514873 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
Prior radiation therapy Adenocarcinoma of prostate | Prior Chemotherapy Adenocarcinoma of prostate | Antiandrogen therapy Adenocarcinoma of prostate
Item
any previous, radiotherapy, or chemotherapy, or more than 4 weeks of androgen deprivation hormonal therapy for the treatment of prostate adenocarcinoma.
boolean
C0279134 (UMLS CUI [1,1])
C0007112 (UMLS CUI [1,2])
C1514457 (UMLS CUI [2,1])
C0007112 (UMLS CUI [2,2])
C0279492 (UMLS CUI [3,1])
C0007112 (UMLS CUI [3,2])
Investigational New Drugs
Item
patients may not be receiving any other investigational agents.
boolean
C0013230 (UMLS CUI [1])
Allergic Reaction Compound Sorafenib Similar | Allergic Reaction Compound Investigational New Drugs Similar
Item
history of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib or other agents used in this study.
boolean
C1527304 (UMLS CUI [1,1])
C1706082 (UMLS CUI [1,2])
C1516119 (UMLS CUI [1,3])
C2348205 (UMLS CUI [1,4])
C1527304 (UMLS CUI [2,1])
C1706082 (UMLS CUI [2,2])
C0013230 (UMLS CUI [2,3])
C2348205 (UMLS CUI [2,4])
HIV Infection | Hepatitis B, Chronic | Hepatitis C, Chronic
Item
known human immunodeficiency virus (hiv) infection or chronic hepatitis b or c.
boolean
C0019693 (UMLS CUI [1])
C0524909 (UMLS CUI [2])
C0524910 (UMLS CUI [3])
Anticoagulation Therapy | Warfarin | Heparin
Item
patients receiving anti-coagulation treatment with an agent such as warfarin or heparin will not be allowed to participate.
boolean
C0003281 (UMLS CUI [1])
C0043031 (UMLS CUI [2])
C0019134 (UMLS CUI [3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial